Literatur
-
1
Andersson B, Mattsson L, Hahn L, Märin P, Lapidus L, Hohn G, Bengtsson B, Björntorp B.
Estrogen
replacement therapy decreases hyperandrogenecity and improves glucose
homeostasis and plasma lipids in postmenopausal women with noninsulin dependent
diabetes mellitus.
J Clin Endocrinol
Metabol.
1997;
82
638-643
-
2
Bounameaux H, de
Moerloose P, Campanne A.
Contraception
orale et substitution hormonale de la menopause.
Schweiz Med
Wschr.
1996;
126
1756-1763
-
3
Collaborative study of cardiovascular disease and
steroid hormone
contraception.
Contraception.
1998;
57
315-324
-
4
Col N F, Eckmann M H, Karas R H, Paucker S G, Goldberg R J, Ross E M, Orr R K, Wong J B.
Patient-specific
decisions about hormone replacement therapy in postmenopausal
womens.
J Am Med
Ass.
1997;
277
1140-1147
-
5
Colditz G A, Willett W C, Stampfer M J. et
al .
Menopause and the risk of coronary heart disease in
women.
N Engl J
Med.
1987;
316
1105-1110
-
6
Colditz G A, Hankinson S E, Hunter D J.
et al .
The use of estrogens and progestins and the risk of breast
cancer in postmenopausal women.
N Engl J
Med.
1995;
332
1589-1593
-
7
Daly E, Vessey M P, Hawkins M M. et
al .
Risk of venous thromboembolism in users of hormone replacement
therapy.
Lancet.
1996;
348
977-980
-
8
Dunn N, Thorogood M, Faragher B. et
al .
Oral contraceptives and myocardial infarction: results of the
MICA case-control study.
Brit Med
J.
1999;
318
1579-1584
-
9
Ettinger P, Friedman G D, Bush R, Quesenburg
jr C P.
Reduced mortality associated with
long-term postmenopausal estrogen therapy.
Obstet
Gynecol.
1996;
87
1-7
-
10
Folsorn A R, Mink P J, Selleres T A, Hong C P, Zheng W, Potter J D.
Hormonal
replacement therapy and morbidity and mortality in a prospective study of
postmenopausal women.
Am J Public
Health.
1995;
85
1128-1132
-
11
Gorsky R D, Koplan J P. et
al .
Relative risks and benefits of longterm estrogen replacement
therapy.
Obstet
Gynecol.
1994;
83
161-166
-
12
Grady D, Rubin S M, Petitti D, Fox C S, Black D, Ettinger B, Ernster V, Cummings S R.
Hormone
replacement therapy to prevent disease and prolong life in postmenopausal
women.
Ann Int
Med.
1992;
117
1038-1041
-
13
Grodstein F, Stampfer M J, Colditz G A.
Postmenopausal
hormone therapy and mortality.
N Engl J
Med.
1997;
336
1769-1775
-
14
Grodstein F, Stampfer M J, Manson J E, Colditz G A, Willet W C, Rosner B, Speizer F, Hennekens C H.
Postmenopausal
estrogen and progestin use and the risk of cardiovascular disaese.
N
Engl J
Med.
1996;
335
453-461
-
15
Grodstein F, Stampfer M J, Goldhaber S Z, Manson J E, Coldis G A, Speizer F E, Willett W C, Hennekens C H.
Prospective
study of exogenous hormones and risk of pulmonary embolism in
women.
Lancet.
1996;
248
1183-1186
-
16
Hennekens C H.
Hormone
replacement therapy: Current perspectives and future directions.
Eur
Heart
J.
1997;
19
1362-1363
-
17
Hertfelder H J, Hanfland P.
Blutgerinnungsveränderungen
unter Ovulationshemmung, in der Schwangerschaft und in der
Postmenopause.
Herz/Kreislauf.
1999;
31
109-112
-
18
Hulley S, Grady D, Bush T, Furberg C, Herrington D, Vittinghoff E. for
the Heart and Estrogen/Progestin Replacement study (HERS) research
group .
Rado○ized ▾rial of
e▴▾roge plu▴ proge▴▾i for
▴ecodar▮ preve▾io of
coroar▮ hear▾ di▴ea▴e i
po▴▾○eopau▴al wo○e.
J Am Med
Ass.
1998;
280
605-623
-
19
Jick H, Derby L E, Myers M W, Vasilaikis C, Newton K M.
Risk
of hosptital admission for idiopathic venous thromboembolism among users of
postmenopausal
estrogens.
Lancet.
1996;
348
981-983
-
20
Jordan V C.
Designer-Östrogene:
Neuartige Prävention gegen Brustkrebs und Osteoporose.
Spektrum
der
Wissenschaft.
1999;
✗
66-73
-
21
Koh K K, Mincemoyer R, Bui B N, Csako G, Pucino F, Guetta V, Waclawiw M, Cannon R O.
Effects
of hormone replacement therapy on fibrinolysis in postmenopausal
women.
N Engl J
Med.
1997;
336
683-690
-
22
Kommission Hormontoxikologie der Deutschen
Gesellschaft für
Endokrinologie .
Östrogen/Gestagen-Substitution
während und nach den
Wechseljahren.
Endokrinologie.
1996;
20
122-125
-
23
Mant J, Painter R, Vessey M.
Risk
of myocardial infarction, angina and stroke in users of oral contraceptives:
updated analysis of a cohort study.
Br J Obstet
Gynaekcol.
1998;
105
890-896
-
24
Mendelsohn M E, Karas R H.
Mechanism
of Disease: The protective effects of Estrogen on the cardiovascular
system.
N Engl J
Med.
1999;
340
1801
-
25
O`Brian J E, Peterson E D, Keeler G P.
Relation
between estrogen replacement therapy and restenosis after percutaneous coronary
interventions.
J Am Coll
Cardiol.
1996;
28
1111-1118
-
26
Oger E, Scarabin P Y.
Assessment
of the risk for venous thromboembolism among users of the hormone replacement
therapy.
Drugs
Aging.
1999;
14
55-61
-
27
Peterson L.
Estrogen
replacement therapy and coronary heart disease.
Curr Opin
Cardiol.
1998;
13
223-231
-
28
Psaty B M, Heckbert S R, Atkins D.
et al .
The risk of myocardial infarction associated with the
combined use of estrogen and progestin in postmenopausal women.
Arch
Int
Med.
1994;
154
1333-1339
-
29
Rich-Edwards J W, Manson J, Hennekens C H, Buring J E.
The
primary prevention of coronary heart disease in women.
N Engl J
Med.
1995;
332
1758-1766
-
30
Rich-Edwards J W, Hennekens C H.
Postmenopuasal
hormones and coronary heart disease.
Curr Opin
Cardiol.
1996;
12
440-446
-
31
Ringe J D, Nickelsen T h.
Raloxifen.
Arzneimitteltherapie.
1999;
17
113-120
-
32
Schunkert H, Danser A H-J, Hense H, Derks F H-M, Kürzinger S, Rigger G A-J.
Effects
of estrogen replacement therapy of the renin-angiotensin system in
postmenopausal
women.
Circulation.
1997;
95
39-45
-
33
Sherif K.
Benefits
and risks of oral contraceptives.
Am J Obstet
Gynecol.
1999;
180
343-348
-
34
Skouby S O.
Oral
contraceptives and venous thrombosis: End of the debate?.
Eur J
Contracept Reprod Health
Care.
1998;
3
59-64
-
35
Stadel B V.
Oral
contraceptives and cardiovascular disease.
N Engl J
Med.
1993;
328
1069-1075
-
36
Stampfer M J, Willett W C, Colditz G A, Rosner B, Speizer F E, Hennekens C H.
A
prospective study of the meonopausal estrogen therapy and coronary heart
disease.
N Engl J
Med.
1985;
313
1044-1049
-
37
Stampfer M J, Colditz G A, Willett W C. et
al .
Postmenopausal estrogen therapy and cardiovascular
disease.
N Engl J
Med.
1991;
325
756-762
-
38
Stampfer M J, Colditz G A.
Estrogen
replacement therapy and coronary heart disase: A quantitative assessment of the
epidemiologic evidence.
Prev
Med.
1991;
20
47-63
-
39
Sullivan J M, El-Zeky F, Vander
Zwang R, Ramanathan K B.
Effect
on survival of estrogen replacement therapy after coronary artery bypass
grafting.
Am J
Cardiol.
1997;
79
847-850
-
40
Sourander L, Rajala T, Makinen I. et
al .
Cardiovascular and cancer morbidity and mortality and sudden
cardiac death in postmenopausal women on estrogen replacement
therapy.
Lancet.
1998;
352
1965-1969
-
41
Todd J, Lawrenson R, Farmer R D, Williams T J, Leyden G M.
Venous
thromboembolic disease and combined oral contraceptives: A reanalysis of the
MedPlus database.
Hum
Reprod.
1999;
14
1500-1005
-
42
Weiss G.
Risk of
venous thromboembolism with third generation oral contraceptives. A
review.
Am J Obstet
Gynecol.
1999;
180
295-301
-
43
The writing group for the PEPI
trial .
Effects of estrogen or Estrogen/Progestin Regimens on
heart disease: Risk factors in postmenopausal women. The postmenopausal
Estrogen/Progestin interventions(PEPI) trial.
J Am Med
Ass.
1995;
273
199-208
-
44
Windler E.
Prävention
kardiovaskulärer Erkrankungen durch Hormonsubstitution in der
Postmenopause.
Zentralbl
Gynäkol.
1996;
118
188-197
Korrespondenz
Privatdozent Dr. W. Lengfelder
Klinik für
Kardiologie und Internistische Intensivmedizin Klinikum
Minden
Postfach
32390 Minden
Telefon: 0571/8013012,
Fax: 0571/8013015
